Drug Profile
Research programme: influenza virus replication inhibitors - OSI Pharmaceuticals/Sankyo
Alternative Names: Influenza virus replication inhibitors research programme - OSI PharmaceuticalsLatest Information Update: 04 Jun 2002
Price :
$50
*
At a glance
- Originator Medical Research Council; OSI Pharmaceuticals; Sankyo
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Influenza virus infections
Most Recent Events
- 04 Jun 2002 Discontinued - Preclinical for Influenza virus infections in Japan (unspecified route)
- 04 Jun 2002 Discontinued - Preclinical for Influenza virus infections in United Kingdom (unspecified route)
- 04 Jun 2002 Discontinued - Preclinical for Influenza virus infections in USA (unspecified route)